HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yen, T.-C. Articles by Lai, C.-H. Search for Related Content PubMed PubMed Citation Articles by Yen, T.-C. Articles by Lai, C.-H.

Defining the Priority of Using ¹⁸F-FDG PET for Recurrent Cervical Cancer

¹ Department of Nuclear Medicine, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
² Biostatistics Consulting Center/Department of Public Health, Chang Gung University, Taoyuan, Taiwan
³ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
⁴ Department of Diagnostic Radiology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
⁵ Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
⁶ Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
⁷ Institute of Nuclear Energy Research, Taoyuan, Taiwan
⁸ Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan

PET with ¹⁸F-FDG has shown its potential in cervical cancer. For maximizing the benefits of this new imaging technology, we aimed to define the prognostic features of recurrent cervical cancer patients for selecting appropriate candidates using ¹⁸F-FDG PET. Methods: Patients enrolled were from 2 independent prospective studies investigating the role of ¹⁸F-FDG PET in cervical cancer patients after definitive treatment with documented failure (CTRP-018) or unexplained elevated tumor marker serum levels (CTRP-016) and proven relapse after PET. A total of 55 eligible patients received PET and CT or MRI. Lesion status was determined from pathologic results or clinical follow-up. The benefits calculated were based on treatment that was modified because of the PET findings. The Cox proportional hazards ratio (HR) was used to select independent prognostic covariates. Results: Thirty-six (65.5%) patients had treatment that was modified due to PET. Primary radiation (HR = 14.62; 95% confidence interval [CI] = 2.74–77.92), squamous cell carcinoma antigen (SCC-Ag) 4 ng/mL (HR = 5.82; 95% CI = 1.53–22.04), and presence of symptoms (HR = 6.24; 95% CI = 1.99–19.61) at recurrence were significant factors associated with poor survival. A scoring system using these covariates defined 3 distinct prognostic groups: score 1 (HR = 1.00); score = 2 (HR = 6.91; 95% CI = 1.49–32.14); and score = 3 (HR = 60.46; 95% CI = 9.68–378.09) (P < 0.0001). Conclusion: Using this risk score, ¹⁸F-FDG PET may offer maximal benefits by selecting appropriate recurrent cervical cancer patients for salvage therapy with precise restaging information.

Key Words: ¹⁸F-FDG PET • recurrent cervical cancer • priority • benefit

Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8A-9A. [Full Text]  

This article has been cited by other articles:

				A. A.M. van der Veldt, M. R. Buist, M. W. van Baal, E. F. Comans, O. S. Hoekstra, and C. F.M. Molthoff Clarifying the Diagnosis of Clinically Suspected Recurrence of Cervical Cancer: Impact of 18F-FDG PET J. Nucl. Med., December 1, 2008; 49(12): 1936 - 1943. [Abstract] [Full Text] [PDF]

				J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma JAMA, November 21, 2007; 298(19): 2289 - 2295. [Abstract] [Full Text] [PDF]

				N. Pandit-Taskar Oncologic Imaging in Gynecologic Malignancies J. Nucl. Med., November 1, 2005; 46(11): 1842 - 1850. [Abstract] [Full Text] [PDF]

				R H Reznek and A Sahdev MR imaging in cervical cancer: seeing is believing: The 2004 Mackenzie Davidson Memorial Lecture Br. J. Radiol., October 1, 2005; 78(Special_Issue_2): S73 - S85. [Full Text] [PDF]

				T. Z. Belhocine 18F-FDG PET Imaging in Posttherapy Monitoring of Cervical Cancers: From Diagnosis to Prognosis J. Nucl. Med., October 1, 2004; 45(10): 1602 - 1604. [Full Text] [PDF]